About | Free Trial

Last Update

2015-09-30T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong David Karpf?

Dr. David Karpf B. MD

Chief Medical Officer

Metabolex , Inc.

Direct Phone: (510) ***-****       

Email: d***@***.com

Metabolex , Inc.

3876 Bay Center Place

Hayward, California 94545

United States

Company Description

Metabolex discovers and develops novel therapeutics to treat type 2 diabetes and related metabolic disorders. It is our goal to bring to the patient breakthrough medicines that improve quality of life. Our deep understanding of the biology of these diseas ... more

Find other employees at this company (34)

Background Information

Employment History

Adj. Clinical Professor of Endocrinology, Gerontology and Metabolism
Stanford University

Chief Medical Officer
Virobay Inc

Executive Director of Clinical Research and Regulatory Affairs
Geron Corporation

Vice President, Clinical and Regulatory Affairs
Calydon , Inc.

Fulltime Endocrine Faculty
University of California , San Francisco

Education



Stanford University School of Medicine



UCSF School of Medicine

B.A.
Psychology and Biology
University of California , Berkeley

M.D.

M.D. degree

University of California , San Diego

MD

Johns Hopkins

MD

UC San Diego Medical School

degrees
Biology and Psychology
University of California , Berkeley

Web References (100 Total References)


ViroBay

www.virobayinc.com, $reference.date [cached]

David B. Karpf MD Chief Medical Officer

...
David B. Karpf MD Chief Medical Officer
David B. Karpf, M.D. has served as our Chief Medical Officer since October 2011. From December 2010 to October 2011, Dr. Karpf served as a life sciences consultant. From January 2004 to December 2010, Dr. Karpf served as Chief Medical Officer and Vice President of Clinical Affairs at Metabolex, Inc., now CymaBay Therapeutics, Inc., where he oversaw the development of clinical programs in various diseases, including type 2 diabetes, gout and dyslipdemia. From May 2001 to January 2004, Dr. Karpf served as Executive Director of Clinical Research and Regulatory Affairs at Geron Corporation, or Geron, a clinical stage biopharmaceutical company, where he oversaw early clinical programs in cancer and regenerative medicine. From May 2000 to May 2001, Dr. Karpf served as Vice President, Clinical and Regulatory Affairs at Calydon, Inc., a company that developed oncolytic virus cancer treatments, which was acquired by Cell Genesis, Inc. in September 2001. From October 1996 to May 2000, Dr. Karpf served as Executive Director of Clinical Research at Roche, where he was responsible for clinical development activities in endocrinology and metabolic bone disease. From August 1991 to December 1996, Dr. Karpf served as Director of Clinical Research at Merck Research Laboratories, where he played a pivotal role in the successful New Drug Application and launch of Fosamax™. Dr. Karpf has also held several academic positions and is currently an adjunct clinical professor of endocrinology at Stanford University School of Medicine. Dr. Karpf received a B.A. in Psychology and Biology from University of California, Berkeley and an M.D. from University of California, San Diego. He completed a residency in Internal Medicine and a fellowship in Endocrinology, Diabetes and Metabolism at University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center, and a post-doctoral fellowship in the Endocrine Unit at University of California, San Francisco School of Medicine.


Metabolex, Inc.

www.metabolex.com, $reference.date [cached]

METABOLEX APPOINTS DAVID B. KARPF, M.D. AS CHIEF MEDICAL OFFICER

February 9, 2004
Metabolex, Inc., a privately held pharmaceutical firm that discovers and develops drugs to treat diabetes and related metabolic diseases, today announced the appointment of David B. Karpf, M.D. as chief medical officer, effective January 30, 2004. Dr. Karpf joins Metabolex from Geron Corporation, where he served as executive medical director, clinical and regulatory affairs since 2001....


Virobay has named David ...

www.in-pharmatechnologist.com, $reference.date [cached]

Virobay has named David Karpf as the new chief medical officer.

At Virobay - a biotech with a portfolio of cathepsin protease inhibitors- Karpf will be responsible for all clinical, regulatory and medical affairs.
Previously, Karpf was chief medical officer and vice president, clinical affairs at Metabolex.
"David joins Virobay at an exciting time," said Robert Booth, Virobay president and CEO.


Virobay has named David ...

www.in-pharmatechnologist.com, $reference.date [cached]

Virobay has named David Karpf as the new chief medical officer.

At Virobay - a biotech with a portfolio of cathepsin protease inhibitors- Karpf will be responsible for all clinical, regulatory and medical affairs.
Previously, Karpf was chief medical officer and vice president, clinical affairs at Metabolex.
"David joins Virobay at an exciting time," said Robert Booth, Virobay president and CEO.


Virobay has named David ...

www.in-pharmatechnologist.com, $reference.date [cached]

Virobay has named David Karpf as the new chief medical officer.

At Virobay - a biotech with a portfolio of cathepsin protease inhibitors- Karpf will be responsible for all clinical, regulatory and medical affairs.
Previously, Karpf was chief medical officer and vice president, clinical affairs at Metabolex.
"David joins Virobay at an exciting time," said Robert Booth, Virobay president and CEO.

Similar Profiles

Other People with this Name (339)

Other people with the name Karpf

Carol Karpf
Wilbanks Partners , LLC

Andy Karpf
Las Vegas

Gary Karpf
Prezacor Inc

Sophie Karpf
MST Services Inc

Cory Karpf
Edgemont School District

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory